SK Bioscience Ltd. and Sanofi Pasteur SA announced June 30 positive results from a phase II study for its 21-valent pneumococcal conjugate vaccine (PCV) candidate called GBP-410, or SP-0202 under Sanofi.
Scripps Research Institute has described nucleoside analogues acting as prodrugs reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Exevir Bio BV has been awarded a 2-year R&D grant of €1.6 million by Flanders Innovation & Entrepreneurship (VLAIO) for preclinical research towards prophylactic and therapeutic solutions for dengue.
Blue Water Biotech Inc. has released preliminary preclinical data supporting the use of its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform to develop a novel mpox vaccine candidate.
One of the characteristics of chronic hepatitis B virus (HBV) infection is T-cell exhaustion, which, in turn, is mediated by the PD-1/PD-L1 axis. Researchers at Oligo Therapeutics Inc. reported on ALG-072571, a potent siRNA PD-L1 inhibitor active against HBV infection mouse models.
SARS-CoV-2 and influenza (flu) viruses share similar clinical manifestations, common transmission mechanisms and target tissues, often overlapping during seasonal outbreaks. In addition, co-infection of these viruses worsens disease severity, emphasizing the pressing need for a vaccine that effectively tackles both.
Recent studies in chronic hepatitis B patients have shown that bepirovirsen, an antisense oligonucleotide (ASO), may be considered a suitable option for the treatment of hepatitis B virus (HBV) infection.
Shionogi & Co. Ltd.’s U.S. subsidiary Shinogi Inc. will acquire San Diego-based Qpex Biopharma Inc. in a deal worth up to $140 million that expands Shionogi’s pipeline of infectious disease agents and also adds to Brii Biosciences Ltd.’s pipeline.
RSS
